Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

PVL after TTVR linked to much lower survival rate, fewer clinical benefits
TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.
SVS quality initiative gathers data to improve vascular care
More than 7,000 physicians from a wide variety of healthcare specialties are already participating in the project.
Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban
When it came to all-cause mortality and ischemic stroke, however, the two popular DOACs were associated with comparable outcomes.
Medline recalls millions of devices due to safety risk—FDA threatens ‘regulatory action’ in warning letter
Millions of angiographic syringes were recalled due to a risk of parts becoming loose or disconnected. The FDA, unhappy with Medline's response to this situation, sent the company a new warning letter.
FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system
The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

CCTA outperforms TEE after LAAO, new meta-analysis confirms

Researchers reviewed data from more than 1,300 patients who underwent both CCTA and TEE after undergoing LAAO. The two modalities were comparable in many ways, but cardiac CT was linked to a few key benefits.

Newsweek ranked the 50 best heart hospitals in the world

New LAAO guidelines: 6 key takeaways for interventional cardiologists and electrophysiologists

SCAI and HRS have collaborated on new guidelines designed to help clinicians make the safest, smartest treatment decisions possible.

Boston Scientific’s Agent Drug-Coated Balloon (DCB), which delivers a therapeutic dose of the anti-proliferative drug paclitaxel to the patient’s scar tissue to prevent ISR from recurring, gained FDA approval on March 1..

Boston Scientific’s coronary DCB gains new Medicare reimbursement

The first coronary DCB to gain FDA approval just received an additional reimbursement that could improve patient access.

PASCAL Precision transcatheter valve repair system

Pascal system from Edwards Lifesciences linked to key benefits after M-TEER, T-TEER

The interventional device, designed to perform both M-TEER and T-TEER, is at the center of two new studies published in EuroIntervention.

Exploring the value of same-day permanent pacemaker implantation after TAVR

Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker.

Pilot study looks at same-day discharge PCI for acute coronary syndromes

Study shows same-day discharge is feasible for carefully selected, uncomplicated ACS patients.

Cardiac surgeon John Puskas, MD, Emory University, says CCTA will make invasive angiography obsolete very soon.

CCTA could make invasive angiography a thing of the past

John Puskas, MD, thinks coronary CT angiography is on its way to completely transforming patient care.

Edwards Lifesciences loses TAVR leader to robotics firm, announces replacement

The change comes at a momentous time for the company's TAVR portfolio, which made history in May by receiving the very first FDA approval for treating asymptomatic severe AS.

Interventional Cardiology

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

SVS quality initiative gathers data to improve vascular care

Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban

Medline recalls millions of devices due to safety risk—FDA threatens ‘regulatory action’ in warning letter

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system